← Eichor
Study identifier: NCT06637007 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Condition: Sarcoma,Soft Tissue · Sarcoma · Sarcoma of Bone  ·  Sponsor: Shanxi Province Cancer Hospital

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.

This description comes directly from the study's public registry record.

Talk to the study team

Xin Wang, Dr  ·  +86 138 1117 6181  ·  WXCAMS@126.com

Rui Wang, Dr  ·  18234142488  ·  240013861@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanxi Cancer HospitalTaiyuan, Shanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06637007